Jeffrey M. Jonas - 09 Feb 2026 Form 4 Insider Report for Generation Bio Co. (GBIO)

Reporting relationship: Director
Issuer ticker: GBIO
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 17:35:38 UTC
Prior SEC filing: 31 Oct 2025
Next SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawna-Gay White, Attorney-in-Fact

Key filing fact

Jeffrey M. Jonas filed Form 4 for Generation Bio Co. (GBIO) on 09 Feb 2026.

Key facts

This page summarizes Jeffrey M. Jonas's Form 4 filing for Generation Bio Co. (GBIO).
7 reported transactions and 7 derivative rows are listed below.
Accepted by SEC: 09 Feb 2026, 17:35.

Change

Previous filing in this sequence was filed on 31 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001042021 Primary reporting owner

JONAS JEFFREY M

Relationship: Director
Address: C/O GENERATION BIO CO., 301 BINNEY ST, SUITE 401, CAMBRIDGE
Signature: /s/ Shawna-Gay White, Attorney-in-Fact
Signature date: 09 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -3,000
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $3.87
Footnotes: F1, F2

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -4,246
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,246
Exercise price: $45.92
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -5,200
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,200
Exercise price: $190.00
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,500
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500
Exercise price: $265.90
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,920
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,920
Exercise price: $61.90
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -2,500
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $48.30
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -6,000
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $33.20
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jeffrey M. Jonas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Footnote F2

Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the "Cash Amount") (each such option, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

Footnote F3

Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.